no desc

Do you know the benefits, risks and feasibility of providing intensive glycemic control based on Gliclazide MR?

Thanks to the ADVANCE Trial, we now know that an intensive glucose control - based on incremental titration of Gliclazide MR and other therapies - is able to reduce HbA1c levels to 6.5% effectively and consistently through time in patients with type 2 diabetes, thus achieving long-term protection. This approach significantly reduced the risk of microvascular events (non-fatal MI, non-fatal stroke and cardiovascular death) and microvascular events (retinopathy and nephropathy) by 10%, in addition to demonstrating a very good safety profile with a low hypoglycemia risk and without any other side effects.​

To know more : Click here

Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.